CY1116080T1 - Συνθεσεις sulfoalkyl ether cyclodextrin και μεθοδοι παρασκευης αυτων - Google Patents

Συνθεσεις sulfoalkyl ether cyclodextrin και μεθοδοι παρασκευης αυτων

Info

Publication number
CY1116080T1
CY1116080T1 CY20151100214T CY151100214T CY1116080T1 CY 1116080 T1 CY1116080 T1 CY 1116080T1 CY 20151100214 T CY20151100214 T CY 20151100214T CY 151100214 T CY151100214 T CY 151100214T CY 1116080 T1 CY1116080 T1 CY 1116080T1
Authority
CY
Cyprus
Prior art keywords
sae
composition
preparing
methods
sulfoalkyl ether
Prior art date
Application number
CY20151100214T
Other languages
English (en)
Inventor
James D Pipkin
Gerold L Mosher
Douglas B Hecker
Original Assignee
Cydex Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37968086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116080(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cydex Pharmaceuticals, Inc. filed Critical Cydex Pharmaceuticals, Inc.
Publication of CY1116080T1 publication Critical patent/CY1116080T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D1/00—Evaporating
    • B01D1/16—Evaporating by spraying
    • B01D1/18—Evaporating by spraying to obtain dry solids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Παρέχεται μία σύνθεση σωματιδίων SAE-CD. Η σύνθεση SAE-CD έχει ένα πλεονεκτικό συνδυασμό φυσικών ιδιοτήτων που δεν βρίσκονται σε γνωστές στερεές μορφές της SAE-CD. Ειδικότερα, η σύνθεση SAE-CD διαθέτει ένα πλεονεκτικό προφίλ φυσικοχημικών και μορφολογικών ιδιοτήτων που μπορεί να προσαρμοστεί σε συγκεκριμένες χρήσεις. Η σύνθεση SAE-CD της εφεύρεσης έχει βελτιωμένη απόδοση ροής και διάλυσης σε σύγκριση με τις γνωστές συνθέσεις της SAE-CD.
CY20151100214T 2005-10-26 2015-03-02 Συνθεσεις sulfoalkyl ether cyclodextrin και μεθοδοι παρασκευης αυτων CY1116080T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20120189690 EP2581078B1 (en) 2005-10-26 2005-10-26 Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
PCT/US2005/038933 WO2007050075A1 (en) 2005-10-26 2005-10-26 Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof

Publications (1)

Publication Number Publication Date
CY1116080T1 true CY1116080T1 (el) 2017-02-08

Family

ID=37968086

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20151100214T CY1116080T1 (el) 2005-10-26 2015-03-02 Συνθεσεις sulfoalkyl ether cyclodextrin και μεθοδοι παρασκευης αυτων
CY20151100626T CY1116517T1 (el) 2005-10-26 2015-07-17 Συνθεσεις sulfoalkyl ether cyclodextrin kai μεθοδοι παρασκευης αυτων
CY20171100746T CY1119471T1 (el) 2005-10-26 2017-07-13 Συνθεσεις σουλφοαλκυλ αιθερας κυκλοδεξτρινη και μεθοδοι παρασκευης αυτων

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20151100626T CY1116517T1 (el) 2005-10-26 2015-07-17 Συνθεσεις sulfoalkyl ether cyclodextrin kai μεθοδοι παρασκευης αυτων
CY20171100746T CY1119471T1 (el) 2005-10-26 2017-07-13 Συνθεσεις σουλφοαλκυλ αιθερας κυκλοδεξτρινη και μεθοδοι παρασκευης αυτων

Country Status (22)

Country Link
US (1) US8049003B2 (el)
EP (5) EP2581078B1 (el)
JP (1) JP5465432B2 (el)
KR (1) KR101152886B1 (el)
CN (1) CN101365459B (el)
AT (1) ATE504305T1 (el)
AU (1) AU2005337613B2 (el)
BR (1) BRPI0520654B8 (el)
CA (2) CA2928065C (el)
CY (3) CY1116080T1 (el)
DE (1) DE602005027415D1 (el)
DK (5) DK2952197T3 (el)
ES (5) ES2364491T5 (el)
HK (4) HK1158978A1 (el)
HU (2) HUE025315T2 (el)
IL (3) IL191081A (el)
LT (1) LT2952197T (el)
MX (1) MX348982B (el)
PL (4) PL2581078T3 (el)
PT (5) PT2335707E (el)
SI (2) SI2335707T1 (el)
WO (1) WO2007050075A1 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5183068B2 (ja) * 2003-12-22 2013-04-17 フィンレイ，ウォーレン，エイチ 大気噴出凍結乾燥法による粉末形成
AU2005237523A1 (en) 2004-04-23 2005-11-10 Cydex Pharmaceuticals, Inc. DPI formulation containing sulfoalkyl ether cyclodextrin
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
WO2009018069A2 (en) * 2007-07-30 2009-02-05 Cydex Pharmaceuticals, Inc Mixtures of cyclodextrin derivatives
WO2009048947A1 (en) * 2007-10-09 2009-04-16 Board Of Regents, The University Of Texas System Methods of treatment of opioid tolerance, physical dependence, pain, and addiction with inhibitors of certain growth factor receptors
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
JP5898196B2 (ja) 2010-08-05 2016-04-13 シガ・テクノロジーズ・インコーポレーテッド Ｓｔ−２４６液体製剤および方法
EP3388066B1 (en) 2011-01-26 2020-11-04 Allergan, Inc. Androgen composition for treating an opthalmic condition
JP5731708B2 (ja) 2011-04-06 2015-06-10 ダウ グローバル テクノロジーズ エルエルシー 新規多糖類誘導体及び剤形
CN104271605B (zh) 2012-02-15 2017-07-25 锡德克斯药物公司 环糊精衍生物的制造方法
JP2015508846A (ja) 2012-02-28 2015-03-23 サイデックス・ファーマシューティカルズ・インコーポレイテッド アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
BR112015008954B1 (pt) 2012-10-22 2021-03-02 Cydex Pharmaceuticals, Inc processos para preparar uma composição de ciclodextrina alquilatada compreendendo uma ciclodextrina alquilatada, para preparar pelo menos 9 lotes consecutivos da mesma e para preparar uma composição farmacêutica
AU2013352369B2 (en) * 2012-11-30 2016-07-28 Novartis Ag. Novel pharmaceutical composition
FI3183295T3 (fi) 2014-08-22 2023-09-25 Cydex Pharmaceuticals Inc Fraktioidut alkyloidut syklodekstriinikoostumukset ja menetelmät niiden valmistamiseksi ja käyttämiseksi
CA2980170A1 (en) 2015-03-19 2016-09-22 Cydex Pharmaceuticals, Inc. Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
EP3097962B1 (de) * 2015-05-29 2020-05-13 Symrise AG Vorrichtung zur herstellung von sprühgetrockneten agglomeraten
EP3525792A4 (en) * 2016-10-11 2020-04-22 Aucta Pharmaceuticals POWDER FOR ORAL SUSPENSION CONTAINING LAMOTRIGIN
EP3618825A4 (en) 2017-05-03 2021-01-20 Cydex Pharmaceuticals, Inc. COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US20230227506A1 (en) 2020-06-18 2023-07-20 The University Of Bristol Fatty Acid Complexes Of Coronavirus Spike Protein And Their Use
WO2022029334A1 (en) 2020-08-07 2022-02-10 Gbiotech S.À.R.L. Combination therapies for treating coronavirus infection
AU2022269311A1 (en) 2021-05-06 2023-11-30 Spepharm Ag Pharmaceutical formulations

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
EP0163836B1 (de) 1984-04-07 1988-10-12 Bayer Ag Verfahren und Vorrichtung zur Herstellung von Granulaten
US4920214A (en) 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
ATE124422T1 (de) 1989-04-12 1995-07-15 Procter & Gamble Festes verbraucherprodukt, welches feinteilige cyclodextrin-komplexe enthält.
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
DE69127256T2 (de) 1990-05-21 1998-02-12 Toppan Printing Co Ltd Cyclodextrinderivat
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
IL111184A (en) 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
FR2735136B1 (fr) 1995-06-08 1997-08-14 Roquette Freres Composition pulverulente d'hydroxypropyl-betacyclodextrine et son procede de preparation.
US5935941A (en) 1997-10-24 1999-08-10 Pitha; Josef Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
DK0889056T3 (da) 1997-07-01 2006-07-17 Pfizer Prod Inc Process for making a cyclodextrin
AU759280C (en) 1998-02-23 2004-01-22 Cyclops, Ehf High-energy cyclodextrin complexes
MA25590A1 (fr) 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
AUPR272901A0 (en) * 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
FR2821844B1 (fr) 2001-03-08 2003-05-23 Roquette Freres Procede de preparation d'une beta-cyclodextrine directement compressible, et beta-cyclodextrine directement compressible ainsi obtenue
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20030028014A1 (en) 2001-04-26 2003-02-06 Chris Sikorski Agglomerated modified cyclodextrin and process for making same
DE10240698A1 (de) 2002-09-04 2004-03-18 Symrise Gmbh & Co. Kg Cyclodextrinpartikel
WO2005042584A2 (en) 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
KR20070007075A (ko) * 2003-12-31 2007-01-12 사이덱스 인크 술포알킬 에테르 시클로덱스트린 및 코르티코스테로이드를함유한 흡입용 제형
AU2005237523A1 (en) * 2004-04-23 2005-11-10 Cydex Pharmaceuticals, Inc. DPI formulation containing sulfoalkyl ether cyclodextrin
ATE464883T1 (de) 2004-07-22 2010-05-15 Bend Res Inc Geschmacksabdeckende formulierung mit einer retardierten wirkstoffformulierung und/oder schnell löslichem cyclodextrin
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20060194762A1 (en) 2004-12-23 2006-08-31 Olaf Reer Composition comprising an epothilone and methods for producing a composition comprising an epothilone
US7629331B2 (en) * 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions

Also Published As

Publication number Publication date
ES2526903T3 (es) 2015-01-16
AU2005337613B2 (en) 2011-04-28
JP2009513773A (ja) 2009-04-02
BRPI0520654B8 (pt) 2021-05-25
PL2952197T3 (pl) 2017-09-29
DK1945228T3 (da) 2011-07-25
DK2583668T3 (en) 2015-01-19
EP1945228B2 (en) 2014-11-05
PL2581078T3 (pl) 2015-07-31
CA2632211C (en) 2016-07-05
PL2583668T3 (pl) 2015-05-29
KR101152886B1 (ko) 2012-07-09
HUE035181T2 (hu) 2018-05-02
CN101365459A (zh) 2009-02-11
EP2335707A1 (en) 2011-06-22
EP1945228B9 (en) 2015-03-11
WO2007050075A1 (en) 2007-05-03
PT1945228E (pt) 2011-07-13
SI2952197T1 (sl) 2017-09-29
SI2335707T1 (sl) 2015-09-30
PL2335707T3 (pl) 2015-10-30
CN101365459B (zh) 2011-11-30
ATE504305T1 (de) 2011-04-15
DK2952197T3 (en) 2017-08-07
EP2583668A1 (en) 2013-04-24
ES2364491T5 (es) 2015-02-19
EP1945228B1 (en) 2011-04-06
IL191081A (en) 2016-03-31
IL244130A0 (en) 2016-04-21
HUE025315T2 (en) 2016-02-29
EP2335707B1 (en) 2015-05-06
CY1116517T1 (el) 2017-03-15
CA2928065C (en) 2019-10-15
PT2581078E (pt) 2015-03-10
HK1184070A1 (en) 2014-01-17
HK1218509A1 (zh) 2017-02-24
LT2952197T (lt) 2017-08-25
IL269619B (en) 2020-07-30
KR20080063526A (ko) 2008-07-04
ES2542893T3 (es) 2015-08-12
IL191081A0 (en) 2009-08-03
JP5465432B2 (ja) 2014-04-09
ES2364491T3 (es) 2011-09-05
US8049003B2 (en) 2011-11-01
EP2952197B1 (en) 2017-04-26
EP2952197A1 (en) 2015-12-09
DK2581078T3 (en) 2015-03-02
CA2632211A1 (en) 2007-05-03
DK1945228T4 (da) 2015-01-12
IL244130B (en) 2020-06-30
PT2952197T (pt) 2017-07-28
CA2928065A1 (en) 2007-05-03
EP1945228A1 (en) 2008-07-23
AU2005337613A1 (en) 2007-05-03
US20090011037A1 (en) 2009-01-08
PT2335707E (pt) 2015-09-10
HK1158978A1 (en) 2012-07-27
MX348982B (es) 2017-07-06
EP2581078A1 (en) 2013-04-17
DK2335707T3 (en) 2015-08-10
EP2581078B1 (en) 2014-12-10
DE602005027415D1 (de) 2011-05-19
EP1945228A4 (en) 2010-04-07
IL269619A (en) 2019-11-28
EP2583668B1 (en) 2014-10-08
BRPI0520654B1 (pt) 2020-08-11
BRPI0520654A2 (pt) 2009-05-19
PT2583668E (pt) 2015-01-05
CY1119471T1 (el) 2018-03-07
ES2532374T3 (es) 2015-03-26
HK1184383A1 (en) 2014-01-24
ES2634670T3 (es) 2017-09-28

Similar Documents

Publication Publication Date Title
IL269619B (en) Preparations of sulfoalkyl other than cyclodextrin and methods for their preparation
EA200701274A1 (ru) Нанодисперсные составы на основе такролимуса
ATE527314T1 (de) Neue verwendung eines polyarylens in form eines geknickten starren stabes und artikel aus polyarylen in form eines geknickten starren stabes
DK3090748T3 (da) Sammensætninger, der omfatter nukleotid- og oligonukleotid-prodrugs
EA200702365A1 (ru) Поливинилхлоридные композиты с наполнителем в виде древесных частиц и вспененные материалы на их основе
BRPI0813341A2 (pt) " uso de compostos, composições curáveis, e, uso de composições curáveis ".
BRPI0909787A2 (pt) composição de moldagem termoplástica, usos da combinação de polieteraminas com óxidos amorfos, e de composições de moldagem trermoplásticas, fibra, folha ou moldagem, e, combinação dos componentes.
ATE446018T1 (de) Süssmittelzusammensetzungen
UA100120C2 (en) 5,6-dihydro-1h-pyridin-2-one compounds
DE602006001148D1 (de) Harzzusammensetzung und auf Basis derselben erhaltenes Formteil
ATE523544T1 (de) Alkylierte aminopropylierte ethyendiamine und verwendungen davon
JP2008149934A5 (el)
EA200800099A1 (ru) Композиции наночастиц мегестрола
DE602006014736D1 (de) Harzzusammensetzung und mehrschichtstruktur, in der diese verwendet wird
TW200712129A (en) Silicone material having outstanding viscosity stability
MX2021006926A (es) Composiciones de eter sulfoalquilico-ciclodextrina y metodos de preparacion de las mismas.
WO2006023882A3 (en) Anti-perspirant compositions with improved properties
ATE493921T1 (de) Toaster
TH68489B (th) องค์ประกอบอัดแบบที่ประกอบรวมด้วยพอลิออกซิเมธิลลีน และซีโอไลท์